Surmodics, Inc. has announced results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study. The results were presented on November 3rd at the 23rd Annual VIVA Conference in Las Vegas, Nevada. The PROWL registry is an open-label, retrospective, multi-center study in the U.S. evaluating the Surmodics Pounce™ Thrombectomy Platform for non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. The analysis demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients, with over 40% experiencing symptoms for more than two weeks prior to intervention. In nearly 80% of cases, no additional clot removal was required after using the device, and procedural success exceeded 90%.